-+ 0.00%
-+ 0.00%
-+ 0.00%

Aroa Biosurgery Maintains FY27 Revenue Guidance at NZ$ 115-125 Million

PUBT·10/21/2026 00:01:44
Listen to the news
Aroa Biosurgery Maintains FY27 Revenue Guidance at NZ$ 115-125 Million
  • Aroa Biosurgery maintained FY27 guidance for revenue of NZ$ 115-125 million and normalized EBITDA of NZ$ 8-11 million.
  • An exclusive co-promotion agreement with Mölnlycke covers Endoform in U.S. post-acute settings, effective October 16, 2026.
  • The arrangement frees resources to expand Myriad adoption in surgery and pursue Symphony's outpatient wound-care opportunity while retaining Endoform manufacturing and supply.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aroa Biosurgery Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610202000PR_NEWS_USPR_____CN76358) on October 21, 2026, and is solely responsible for the information contained therein.